$131.06
+0.35 (+0.27%)
Performance
1D
—
1W
—
1M
—
3M
+21.46%
6M
+65.55%
1Y
+1,127.73%
YTD
+30.34%
Open$130.71
Previous Close$130.71
Day High$133.40
Day Low$129.23
52W High$151.02
52W Low$9.51
Volume—
Avg Volume1.44M
Market Cap6.34B
P/E Ratio—
EPS$-3.78
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$105.59
Above
SMA 200
$59.11
Above
RSI (14)
39.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
17 analysts
Price Target
-80.5% upside
Current
$131.06
$131.06
Target
$25.56
$25.56
$16.07
$25.56 avg
$38.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |
| Rev Growth | +6.2% | -3.6% | +12.6% |
| Debt/Equity | 1.11 | 1.11 | 1.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |